Min Zhan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Min Zhan has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Chaomin Huang
State Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangzhou City Key Laboratory of Precision Chemical Drug Development, Guangzhou, 510630, China
1 shared publicationCong Liu
International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education, College of Pharmacy, Jinan University, No. 601 Huangpu Avenue West, Guangzhou, 510530, China
1 shared publication- Fangzhan Chen1 shared publication
Haowen Ma
College of Chemistry and Materials Science, Zhejiang Normal University, No. 688 Yingbin Road, Jinhua, Zhejiang Province, 321004, China; International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education, College of Pharmacy, Jinan University, No. 601 Huangpu Avenue West, Guangzhou, 510530, China
1 shared publicationHuilan Xiong
International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education, College of Pharmacy, Jinan University, No. 601 Huangpu Avenue West, Guangzhou, 510530, China
1 shared publication- Junjie Cheng1 shared publication
Latest Publications
- 15 December 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 283, 117166
Discovery of the first examples of right open reading frame kinase 2 (RIOK2) molecular glue degraders
- 15 December 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 283, 117166
Discovery of the first examples of right open reading frame kinase 2 (RIOK2) molecular glue degraders
- Open Access
- 15 September 2023
- Published by MDPI AG in Preprints.org
A Retrospective Analysis of Spontaneous Reports of Suspected Adverse Drug Reactions to Triptorelin Acetate in a Tertiary Pediatric Medical Center: Still a Lot of Preventable Harm
Background: Although triptorelin acetate (TA) is generally considered a safe medication, severe adverse drug reactions (ADRs) to triptorelin have occurred. In this study, we present the largest retrospective analysis of ADRs related to TA during the treatment of pediatric central precocious puberty. Methods: We describe a total of 38 suspected cases of TA-induced ADRs reported to the pharma-covigilance center of Shenzhen Children’s Hospital from September 2015 to December 2022. Causality assessment was carried out using the validated Kramer’s algorithm. The severity of ADRs was evaluated using the Modified Hartwig and Siegel Scale. Results: The most common ADRs attributed to TA were damage to the cutaneous tissues (29.3%) and reactions affecting the systemic and digestive systems (20.7%). The majority (61.1%) of ADRs occurred within 2 hours of administration. Among the 12 patients with severe ADRs, the three most frequent symptoms were anaphylactic reactions, hip synovitis, and arthralgia. Additional-ly, six patients experienced ADRs due to a change in the manufacturing process. Conclusion: The majority of ADRs observed in pediatric cases were type I anaphylactic reactions, which are rare but life-threatening. It is advisable to perform skin prick tests and intradermal tests when switching pharmaceutical manufacturers.
- 15 September 2023
- Published by MDPI AG in Preprints.org
Open AccessA Retrospective Analysis of Spontaneous Reports of Suspected Adverse Drug Reactions to Triptorelin Acetate in a Tertiary Pediatric Medical Center: Still a Lot of Preventable Harm
Background: Although triptorelin acetate (TA) is generally considered a safe medication, severe adverse drug reactions (ADRs) to triptorelin have occurred. In this study, we present the largest retrospective analysis of ADRs related to TA during the treatment of pediatric central precocious puberty. Methods: We describe a total of 38 suspected cases of TA-induced ADRs reported to the pharma-covigilance center of Shenzhen Children’s Hospital from September 2015 to December 2022. Causality assessment was carried out using the validated Kramer’s algorithm. The severity of ADRs was evaluated using the Modified Hartwig and Siegel Scale. Results: The most common ADRs attributed to TA were damage to the cutaneous tissues (29.3%) and reactions affecting the systemic and digestive systems (20.7%). The majority (61.1%) of ADRs occurred within 2 hours of administration. Among the 12 patients with severe ADRs, the three most frequent symptoms were anaphylactic reactions, hip synovitis, and arthralgia. Additional-ly, six patients experienced ADRs due to a change in the manufacturing process. Conclusion: The majority of ADRs observed in pediatric cases were type I anaphylactic reactions, which are rare but life-threatening. It is advisable to perform skin prick tests and intradermal tests when switching pharmaceutical manufacturers.